A mathematical model suggests that existing HPA-targeting drugs failed in clinical trials for mood disorders because the ...
The following is a summary of “Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone ...
The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...
The consequences of primary aldosteronism mainly result from the activation of the mineralocorticoid receptor. Two of these ...
The message is that an early decrease in eGFR with finerenone should not lead to stopping the medication, say HF experts.
Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.
Bayer, meanwhile, shared phase 3 data on its nonsteroidal mineralocorticoid receptor antagonist Kerendia in September and began prepping for approval filings. Kajal Jaddoo, senior pharma analyst ...
Balcinrenone acts by targeting mineralocorticoid receptor. It is administered through oral route as a capsule form. Dapagliflozin acts by targeting sodium-glucose cotransporter 2 (SGLT2). GlobalData, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback